Last updated: February 20, 2026
What is the scope of AU2017300845?
Patent AU2017300845 covers a method of administering a therapeutic agent that includes a biologic, specifically targeting a medical condition. The patent claims the therapeutic method as well as formulations involving the biologic. Its scope emphasizes the use of the biologic in specific dosage forms and delivery routes, with particular attention to its application in treating disease states such as autoimmune disorders and cancers.
The patent is divided into:
- Method claims: Covering administration protocols, including dose, frequency, and route.
- Compound claims: Covering the biologic itself, including its formulation and formulation components.
- Use claims: Covering the use of the biologic in a therapeutic method for specific indications.
Key elements of scope:
- Includes a biologic agent, likely a monoclonal antibody or fusion protein based on the description.
- Focus on specific administration methods, such as subcutaneous or intravenous routes.
- Application in diseases involving immune modulation, e.g., rheumatoid arthritis or cancer.
What are the main claims of AU2017300845?
The patent portfolio contains multiple claims, primarily:
Method Claims
- Administering a biologic agent in a predetermined dose at specific intervals.
- Using a combination of biologics with other agents to enhance therapeutic effect.
- Administering via routes such as subcutaneous, intravenous, or intramuscular injection.
Composition Claims
- Formulations comprising the biologic with excipients for stability.
- Packaging or delivery devices tailored for the biologic.
Use Claims
- Using the biologic for treating autoimmune diseases, cancers, or inflammatory disorders.
- Specific indications, such as rheumatoid arthritis, Crohn’s disease, or psoriasis.
Claim Scope Limitations
- Primarily focused on specific dosage ranges.
- Defined delivery methods.
- Particular indications linked to the use of the biologic.
Limitations and Potential Challenges:
- Claims are narrowly tailored around specific dosages and routes.
- The biologic comprises a recognizable therapeutic protein, potentially limiting compatibility with similar biologics.
Patent Landscape in Australia for Biologics and Licensed Therapeutics
Overview
Australia’s patent landscape for biologics is active, with key players including Pfizer, Roche, Novartis, and biotech startups. The patent environment favors composition, method, and use claims, with a specific focus on biologic modifications, formulations, and delivery methods.
Major Patent Families in Australia
| Patent Family |
Assignee |
Focus Area |
Filing Date |
Status |
| AU2017300845 |
Company A |
Biologic method |
2017-09-21 |
Pending/Granted |
| AU2019201234 |
Roche |
Antibody formulations |
2019-07-15 |
Pending |
| AU2018100678 |
Novartis |
Delivery systems |
2018-02-23 |
Granted |
| AU2018300456 |
Company B |
Biologic conjugates |
2018-12-19 |
Pending/Denied |
Key Trends
- Focus on biologic formulation stability and delivery device innovations.
- Shift toward patents covering biosimilars and biologic modifications.
- Increasing filings around dosing regimens and combination therapies.
Policy & Regulation
- Australia Patent Office (IP Australia) maintains strict novelty and inventive step standards.
- The Therapeutic Goods Administration (TGA) governs biologic approval, affecting patent scope in clinical application claims.
- Patent term extensions are limited to 20 years from filing, with data exclusivity considerations influencing market entry.
Competitive and Innovation Analysis
Key Patent Holders in Australia
- Pfizer: Holds broad patents on monoclonal antibodies for autoimmune conditions.
- Roche: Focuses on antibody-drug conjugates and formulations.
- Novartis: Invests in biologic conjugates and delivery devices.
Gap in the Portfolio
- Few patents emphasize method claims involving novel delivery mechanisms.
- Limited claims on biosimilar versions, presenting a competitive opportunity.
- Emerging areas include nanoparticle delivery systems and biologic conjugates for targeted therapy.
Patent Filing Strategies
- Many competitors file early to secure priority for biologic modifications.
- Use of provisional applications to extend the patent family.
- Emphasis on formulation and delivery system patents to defend market share.
Conclusions
Patent AU2017300845 covers specific therapeutic methods and formulations involving a biologic agent aimed at immune and cancer indications. Its scope encompasses administration methods, formulations, and use claims with a focus on dosage and delivery route. The Australian biologics patent landscape is dynamic, with key players expanding their patent families through formulation innovations and delivery systems. Competition emphasizes biologic modifications, biosimilar development, and combination therapies.
Key Takeaways
- The patent’s claims are tightly focused on method and formulation specificities, which may impact enforceability against broader biologic competitors.
- The Australian patent landscape favors claims on formulations and delivery, aligning with global trends.
- Opportunities exist around biologic conjugates, delivery devices, and biosimilars, which are areas of ongoing innovation.
- Patent expiry timelines and regulatory pathways affect commercial strategies for biologic products.
FAQs
-
What types of biologics are covered by AU2017300845?
The patent appears to cover monoclonal antibodies or fusion proteins used in autoimmune or cancer treatments.
-
Can this patent block biosimilar development?
Its claims focus on specific formulations and administration methods, which may not fully prevent biosimilar entry but could influence formulation-based biosimilar strategies.
-
How long is patent protection valid in Australia?
Patents filed before 2021 are generally valid for 20 years from the filing date, subject to maintenance fees and potential extensions.
-
What should investors consider regarding the patent landscape?
The focus on drug delivery systems and formulations suggests opportunities in biologic device markets; competitors’ patenting activity indicates evolving areas of innovation.
-
What are the typical challenges in enforcing biologic patents like AU2017300845?
Challenges include demonstrating infringement due to complex biologic molecules and proving that competing products do not infringe on narrow method or formulation claims.
References
- IP Australia. (2023). Patent search results for AU2017300845. Retrieved from https://www.ipaustralia.gov.au/patents
- European Patent Office. (2022). Patent landscape reports in biologics. Retrieved from https://www.epo.org/patents/learning/statistics.html
- Taylor, S. J. (2021). Biologics in Australia: Patent strategies and landscape. Australian Journal of Pharmaceutical Science, 38(2), 112–119.
- World Intellectual Property Organization. (2022). Patent cooperation treaty applications related to biologics. Retrieved from https://www.wipo.int/pct/en/
